Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28488917 | 0.78 | SHBG (0.43) | EPHX1SHBG | |
| SCHEMBL11668319 | 0.77 | EPHX1 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5597949 | 0.77 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5598316 | 0.77 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5597950 | 0.77 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL7888229 | 0.76 | SHBG (0.39) | SHBG | |
| SCHEMBL2035572 | 0.76 | TP53 (0.52) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL8775662 | 0.75 | SHBG (0.40) | MAPTEPHX1SHBG | |
| SCHEMBL16892649 | 0.74 | ALDH1A1 (0.37) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL11869138 | 0.74 | TP53 (0.35) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | TP53 3943/4885KDM4E 1375/4885GMNN 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.